Solid Tumor, Adult
Conditions
Brief summary
This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.
Interventions
DRUGLifirafenib
RAF Dimer Inhibitor
DRUGmirdametinib
MEK Inhibitor
Sponsors
SpringWorks Therapeutics, Inc.
BeiGene
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Part A will consist of dose escalation and dose-finding components to establish the max tolerated dose and/or recommended Phase 2 dose Part B will investigate efficacy and further evaluate the PK, safety, and tolerability of the combination of PD-0325901 and BGB-283 (lifirafenib).
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: 1. Able to provide informed consent 2. Age 18 on day of signing informed consent form (ICF) or of the legal age of consent in the jurisdiction in which the study is taking place 3. Advanced or metastatic, unresectable tumors (other than patients with tumors of the brain or central nervous system) who have experienced disease progression * Part A: NSCLC, CRC, ovarian cancer, endometrial cancer, thyroid cancer, melanoma, pancreatic cancer, and other) * Part B: NRAS mutated solid tumors must have a known mutation status and a histologically or cytologically confirmed advanced or refractory solid tumor. Up to 40% Melanoma and Up to 20% CRC. 4. Must have archival tumor tissue or agree to tumor biopsy 5. Measurable disease per RECIST 1.1 6. Eastern Cooperative Oncology Group performance status of less than or equal to 1 7. Life expectancy is greater than 12 weeks of the signing of ICF. 8. Adequate organ function and no transfusion within 14 days of first dose. 9. Females are of non-child bearing potential or willing to use contraception. 10. Males vasectomized or agree to use contraception. Key
Exclusion criteria
1. Central Nervous System metastasis 2. Any retinal pathology considered to be a risk factor for central serous retinopathy 3. History of glaucoma 4. Active parathyroid disorder or history of malignancy associated hypercalcemia 5. Clinically significant cardiac disease within the past 6 months of signing ICF. 6. LVEF less than 50% 7. Abnormal QT interval at Screening 8. Severe uncontrolled systemic disease 9. HIV 10. Clinically significant active or known history of liver disease. (Hepatitis B and Hepatitis C) 11. Hemorrhage or bleeding event at NCI-CTCAE v5.0 Grade 3 or higher within 28 days of first dose. 12. history of or ongoing Von Willebrand disease and/or other past or present bleeding disorders 13. Increased serum calcium 14. Inability to swallow oral medications 15. Ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks. No chemotherapy, immunotherapy, biologic therapy, hormonal, or molecular targeted therapy within prior 2 weeks 16. Concomitant systemic or glucocorticoid therapy within 2 weeks 17. Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose or anticipates need for major surgery while on study 18. Concomitant medicines that are strong CYP3A inhibitors 19. History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of treatment from these drugs 20. Underlying medical conditions in investigator's opinion to be unfavorable to be a part of the study 21. Has been administered a live vaccine within 4 weeks (28 days) of initiation of study treatment. NOTE: injectable seasonal vaccines for influenza and COVID-19 are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed. NOTE: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events and Serious Adverse Events | Approximately 2 years from date of the participants enrollment | Incidence and severity of AEs and SAEs and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0 |
| The incidence of DLT events and treatment-emergent AEs (TEAEs) | Approximately 2 years from date of the participants enrollment | — |
| Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor types | Approximately 2 years from date of the participants enrollment | — |
Countries
Australia, United States
Outcome results
None listed